Drug Approval | March 29, 2023
Zydus receives final approval from USFDA for Loperamide Hydrochloride Capsules
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
Loperamide Hydrochloride Capsules USP, 2 mg had annual sales of US $34.7 million in the United States
Doxepin Hydrochloride capsule is indicated to treat mental/mood problems such as depression and anxiety
Lubiprostone capsule is indicated to treat certain types of constipation (chronic idiopathic constipation and irritable bowel syndrome with constipation)
Tofacitinib Tablets, 5 mg and 10 mg had annual sales of US $900 million in the United States (IQVIA MAT December 2022)
According to IQVIA sales data for the 12-month period ending January 2023, the Compazine Tablets, 5 mg and 10 mg market achieved annual sales of approximately US $26.9 million
The Phase 3 data presented at AAD include a comprehensive review of the THRIVE-AA2 results and further elaborate the topline data reported in August 2022
Cleocin Hydrochloride Capsules market achieved annual sales of approximately US $33.6 million
Olanzapine Orally Disintegrating Tablets are used to treat certain mental/mood conditions
The agreement is for USFDA approved Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate and Amphetamine Sulfate Tablets
Erythromycin Tablets USP, 250 mg and 500 mg are used to prevent and treat infections in many different parts of the body
Subscribe To Our Newsletter & Stay Updated
